Z. Zhan

发表

Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs.

T. Fojo, M. Blagosklonny, A. Iglesias, 1998, Biochemical and biophysical research communications.

Histone deacetylase inhibitors: emerging mechanisms of resistance.

S. Bates, Z. Zhan, R. Robey, 2011, Molecular pharmaceutics.

Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176)

T. Fojo, S. Bates, Z. Zhan, 2006, Clinical Cancer Research.

Increased MDR 1 Expression in Normal andMalignant Peripheral BloodMononuclear Cells Obtained from Patients Receiving Depsipeptide ( FR 901228 , FK 228 , NSC 630176 )

T. Fojo, S. Bates, Z. Zhan, 2006 .

Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P‐glycoprotein or MRP overexpression

S. Bates, S. Scala, Z. Zhan, 1997, Journal of cellular biochemistry.

Measuring MDR-1 by Quantitative RT-PCR.

S. Bates, Z. Zhan, E. Gamelin, 1999, Methods in molecular medicine.

ABC Transport Genes in Mitoxantrone-resistant Cells : Demonstration of Homology Molecular Cloning of cDNAs Which Are Highly Overexpressed

T. Litman, T. Fojo, S. Bates, 1998 .

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

M. Gottesman, S. Bates, Z. Zhan, 2013, Blood.

Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.

W. Wilson, S. Steinberg, R. Wittes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The challenge of exploiting ABCG2 in the clinic.

S. Bates, C. Ieranò, Z. Zhan, 2011, Current pharmaceutical biotechnology.

Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line

T. Litman, S. Bates, Z. Zhan, 2008, Molecular and Cellular Biology.

Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration

S. Bates, C. Ieranò, S. Scala, 2013, Cancer biology & therapy.

Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway

S. Bates, Z. Zhan, R. Robey, 2011, Molecular Cancer Research.

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma

S. Steinberg, T. Fojo, S. Bates, 2010, British journal of haematology.

Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay

W. Wilson, S. Bates, A. Fojo, 1997 .

Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors

S. Pittaluga, S. Bates, C. Ieranò, 2013, Cell cycle.

Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.

W. Wilson, S. Bates, A. Fojo, 1997, Blood.

Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization*

T. Fojo, Yoon-Koo Kang, D. Sackett, 1997, The Journal of Biological Chemistry.

Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.

Z. Zhan, R. Robey, M. Stetler-Stevenson, 1995, Blood.

Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.

Torben Skovsgaard, Andrea Abati, T. Litman, 2002, Biochimica et biophysica acta.

Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration

A. Monks, C. Hose, T. Fojo, 1997, Cancer Chemotherapy and Pharmacology.

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

S. Bates, Z. Zhan, R. Robey, 2004, Blood.

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2

Thomas Ried, S. Bates, T. Ried, 2009, Molecular Cancer Therapeutics.

Clinical reversal of multidrug resistance.

W. Wilson, A. Monks, C. Hose, 1996, Stem cells.

Clinical Reversal of Multidrug Resistance

W. Wilson, A. Monks, C. Hose, 1996, The oncologist.

Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer

T. Fojo, T. Knutsen, P. Giannakakou, 2000, Oncogene.

Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma

S. Bates, Z. Zhan, K. To, 2006, Molecular and Cellular Biology.

Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

T. Litman, T. Fojo, S. Bates, 1999, Cancer research.

Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.

T. Fojo, S. Bates, T. Aikou, 2001, The Journal of clinical endocrinology and metabolism.

Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.

T. Fojo, F. Landoni, P. Giannakakou, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors.

W. Wilson, T. Fojo, S. Bates, 1998, Blood.

Reversal of multidrug resistance.

W. Wilson, A. Fojo, Z. Zhan, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T. Fojo, Z. Zhan, N. Sarlis, 2001, The Journal of clinical endocrinology and metabolism.